ストックスクリーナーアプリを入手
17.28
3.57%
-0.64
アフターアワーズ：
17.28
前日終値:
$17.92
開ける：
$17.87
24時間の取引高:
402.14K
Relative Volume:
1.36
時価総額：
$655.65M
収益：
$95.07M
当期純損益:
$-60.37M
株価収益率:
-10.61
EPS:
-1.6291
ネットキャッシュフロー:
$-50.92M
1週間 パフォーマンス:
-5.98%
1か月 パフォーマンス:
+6.01%
6か月 パフォーマンス:
-19.96%
1年 パフォーマンス:
-2.59%
1日の値動き範囲:
$17.07
$18.13
1週間の範囲:
$17.07
$18.80
52週間の値動き範囲:
$10.85
$24.33
Ceribell Inc Stock (CBLL) Company Profile
Compare CBLL vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CBLL
Ceribell Inc
|
17.28 | 705.35M | 95.07M | -60.37M | -50.92M | -1.6291 |
ABT
Abbott Laboratories
|
88.50 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
301.14 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.14 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.95 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.68 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Ceribell Inc Stock (CBLL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-21 | 開始されました | Raymond James | Strong Buy |
| 2025-06-24 | 開始されました | BTIG Research | Buy |
| 2025-04-04 | 開始されました | Ladenburg Thalmann | Buy |
| 2024-11-05 | 開始されました | BofA Securities | Buy |
| 2024-11-05 | 開始されました | Canaccord Genuity | Buy |
| 2024-11-05 | 開始されました | JP Morgan | Overweight |
| 2024-11-05 | 開始されました | TD Cowen | Buy |
| 2024-11-05 | 開始されました | William Blair | Outperform |
すべてを表示
Ceribell Inc (CBLL) 最新ニュース
High-Profile Insider Move Shakes Up Investor Buzz at Ceribell, Inc. - TipRanks
Insider Sell Alert: Joseph Taylor Sells 5,500 Shares of CeriBell Inc (CBLL) - GuruFocus
Ceribell director Joseph Taylor sells $101,255 in common stock By Investing.com - Investing.com South Africa
Ceribell director Joseph Taylor sells $101,255 in common stock - Investing.com
Ceribell, Inc. launches FDA-cleared device for bedside diagnosis and delirium monitoring - Traders Union
Ceribell Insider Sold Shares Worth $714,870, According to a Recent SEC Filing - Moomoo
CBLL Q1 2026 Earnings: EPS Misses Estimates as Losses Widen, Shares DeclinePre-Earnings Drift - newsline.com
Ceribell CEO Chao sells $714,870 in common stock By Investing.com - Investing.com Nigeria
Ceribell CEO Chao sells $714,870 in common stock - Investing.com
CeriBell Inc. (CBLL) Shows Strength with 4% Gain: Technical Levels and Market ContextIsland Reversal - newsline.com
FDA-approved ceribell EEG shortens seizure diagnosis by monitoring brain activity - CBS News
Ceribell Announces New Critical Care Medicine Publication Reinforcing Link Between Seizure Burden Measured by Clarity AI Algorithm and Neurological Outcomes - The Manila Times
Ceribell Announces New Critical Care Medicine Publication - GlobeNewswire
CBLL Q1 2026 Earnings: Wider-than-Expected Loss Disappoints InvestorsSlow Growth Warning - newsline.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
William Blair Maintains Ceribell(CBLL.US) With Buy Rating - Moomoo
Ceribell Announces Director Elections at 2026 Annual Meeting - The Globe and Mail
CBLL Technical Analysis | Trend, Signals & Chart Patterns | CERIBELL INC (NASDAQ:CBLL) - ChartMill
CeriBell (CBLL) 10K Form and Latest SEC Filings 2026 - MarketBeat
InvestingPro’s Fair Value warned of CeriBell crash 17 months ago By Investing.com - Investing.com
CBLL Q1 2026 Earnings: Wider-than-Expected Loss Raises ConcernsBanking Earnings Report - newsline.com
Ceribell Leadership Unloads Shares in a Wave of Insider Stock Moves - TipRanks
CeriBell (CBLL) Holds Near Support Amid Modest GainsFibonacci Fan - newsline.com
EEG adoption accelerates in urgent seizure detection, Ceribell, Inc. pushes - Traders Union
CeriBell Inc. (CBLL) Q1 2026 Earnings: EPS Misses Estimates by 30.7%, Stock Edges HigherEarnings Seasonality - newsline.com
Ceribell CEO to present at William Blair Growth Stock Conference on June 3, 2026 - Pluang
Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference - Moomoo
Earnings call transcript: Ceribell Inc. Q1 2026 misses EPS, revenue up - Investing.com Nigeria
Bank of America Securities Remains a Buy on Ceribell, Inc. (CBLL) - The Globe and Mail
Canaccord Genuity maintains Ceribell (CBLL) buy recommendation - MSN
Ceribell anticipates $112M-$116M 2026 revenue while targeting delirium NTAP of up to $2,171 per patient - MSN
CeriBell Sees ‘Early Innings’ Growth as Hospital Accounts and Usage Hit Records - Yahoo Finance
Ladenburg Thalmann Maintains Ceribell(CBLL.US) With Buy Rating, Maintains Target Price $32 - Moomoo
Middle East Tensions Threaten Ceribell’s Supply Chain, Shipping Routes, and Margins - TipRanks
Ceribell’s Earnings Call Signals Growth Over Profits - The Globe and Mail
TD Cowen Maintains Ceribell(CBLL.US) With Buy Rating, Maintains Target Price $29 - Moomoo
A Quick Look at Today's Ratings for Ceribell(CBLL.US), With a Forecast Between $25 to $29 - Moomoo
Canaccord lowers Ceribell stock price target on valuation compression By Investing.com - Investing.com Australia
Canaccord lowers Ceribell stock price target on valuation compression - Investing.com
Ceribell: Buy Rating Reiterated on Strong Q1 Momentum and Expanded TAM, $28 Price Target Maintained - TipRanks
Ceribell, Inc. (CBLL) reports Q1 loss, beats revenue estimates - MSN
CeriBell Q1 Earnings Call Highlights - inkl
CeriBell (CBLL) Q1 2026 Earnings Transcript - AOL.com
CeriBell, Inc. (CBLL) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
CeriBell Q1 Loss Widens, Revenue Rises; Lifts Full-Year Revenue Guidance - Moomoo
Ceribell Inc (NASDAQ:CBLL) Q1 Revenue Beats Estimates, Net Loss Widens, Full-Year Guidance Raised - ChartMill
Ceribell Inc (CBLL) 財務データ
収益
当期純利益
現金流量
EPS
2.43%
大文字化:
|
ボリューム (24 時間):